OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
112
Results
Show all
Save search
Copy query
Show results for
Unknown
(108)
Genomics
(2)
Transcriptomics
(1)
Proteomics
(1)
Organisms
Homo sapiens
(4)
Repository
biostudies-arrayexpress
(2)
EGA
(1)
pride
(1)
Tissue
Lung
(1)
Uterine endometrium
(1)
Technology Type
Bottom-up proteomics
(1)
Data-dependent acquisition
(1)
Mass Spectrometry
(1)
Instrument Platform
Illumina HiSeq 2000
(1)
Publication Date
2018
(1)
2011
(1)
2025
(1)
Study type
Comparative genomic hybridization by array
(1)
DNA-seq
(1)
Release Date
2020
(22)
2022
(17)
2024
(9)
2016
(7)
2015
(7)
2021
(6)
2019
(6)
2023
(5)
2018
(4)
2025
(4)
2017
(4)
2011
(3)
2026
(3)
2014
(3)
2009
(3)
2013
(2)
2012
(2)
2008
(2)
2010
(1)
Lab affiliation
Chair of Proteomics and Bioanalytics, Technical University of Munich, Bavaria, Germany
(1)
Previous
page
1 / 12
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
12
Next
page
Sort
by:
Relevance
Page size
10
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.
Not available
S-EPMC11814523
|
biostudies-literature
Cite
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
Not available
S-EPMC11609519
|
biostudies-literature
Cite
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.
Not available
S-EPMC11741176
|
biostudies-literature
Cite
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
Not available
S-EPMC8986610
|
biostudies-literature
Cite
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
Not available
S-EPMC8078259
|
biostudies-literature
Cite
Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
Not available
S-EPMC7477726
|
biostudies-literature
Cite
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Not available
S-EPMC11022982
|
biostudies-literature
Cite
Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling.
Not available
S-EPMC9789386
|
biostudies-literature
Cite
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Not available
S-EPMC8796656
|
biostudies-literature
Cite
MicroRNA-19b predicts widespread pain and posttraumatic stress symptom risk in a sex-dependent manner following trauma exposure.
Not available
S-EPMC6923535
|
biostudies-literature
Cite
Previous
page
1 / 12
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
12
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
